Experience the Quality With Free AOCNP Exam Questions That Helps Candidates Pass

Safe handling standards for antineoplastic agents require engineering controls and personal protective equipment. Using a CSTD during preparation and administration reduces aerosolization and surface contamination. Chemotherapy-tested double nitrile gloves (changed at recommended intervals), disposable impermeable gowns, eye/face protection for splash risk, and priming IV tubing with non-drug diluent before connecting to the patient are core elements. Manual needle recapping (Option D) increases needlestick injuries and is contraindicated. Priming with drug (Option A) increases contamination risk. Single vinyl gloves (Option C) are inadequate. The APRN leads development of policies aligned with national standards, ensures staff training/competency, audits compliance (wipe tests, spill drills), and coordinates waste segregation and spill management. Patient/caregiver education on handling body fluids at home after certain drugs also falls within APRN scope. Documentation of exposures and access to post-exposure evaluation supports worker safety culture.

Temozolomide with cranial radiation increases risk for opportunistic infections, notably Pneumocystis jirovecii pneumonia (PJP). Clinical standards recommend PJP prophylaxis—first line is trimethoprim–sulfamethoxazole (TMP-SMX) given on daily or thrice-weekly schedules; alternatives (atovaquone, dapsone, or inhaled pentamidine) are used for sulfa allergy or intolerance with appropriate G6PD screening when relevant. Herpes prophylaxis (acyclovir) may be added based on steroid use or institutional policy but does not replace PJP prevention. Routine fluoroquinolone prophylaxis (Option D) is not standard and raises resistance/C. difficile concerns. The APRN should counsel on adherence, monitor for cytopenias (TMP-SMX can exacerbate myelosuppression), manage rash or GI intolerance, and coordinate vaccinations (inactivated influenza; avoid live vaccines during immunosuppression). Baseline and periodic CBCs guide therapy, and ongoing steroid exposure further elevates PJP risk. Clear documentation of start/stop criteria—often continuing until lymphopenia resolves or radiation/temozolomide phase ends—prevents gaps in protection.

Carboplatin at AUC ≥4 is considered at least moderately emetogenic and benefits from NK1 receptor antagonist augmentation. Optimal prophylaxis includes a 5-HT3 receptor antagonist (e.g., palonosetron), dexamethasone, and an NK1 antagonist (aprepitant/fosaprepitant or netupitant when combined with palonosetron). Olanzapine (typically 5–10 mg) further improves control of both nausea and emesis and is reasonable when prior cycles showed bothersome symptoms. Palonosetron + dexamethasone alone (Option A) undercovers substance P–mediated pathways and increases delayed-phase failure. Scopolamine (Option C) targets vestibular nausea and is not primary for chemotherapy-induced nausea/vomiting. Dexamethasone alone (Option D) is inadequate. The APRN should check interaction profiles (CYP3A4 with NK1s), adjust dexamethasone dose if using netupitant (due to steroid-sparing effect), provide a rescue plan (prochlorperazine or metoclopramide), and reinforce nonpharmacologic measures (small frequent meals, hydration). Document prior cycle outcomes to tailor future prophylaxis and schedule follow-up to capture breakthrough events promptly.

Survivorship care focuses on surveillance for recurrence based on evidence-based intervals, monitoring and managing late/long-term effects, and promoting health maintenance. After anthracycline exposure, patients with additional cardiac risk factors (e.g., hypertension, obesity) merit consideration of baseline and periodic echocardiography to detect asymptomatic LV dysfunction. Lifestyle counseling—weight management, aerobic/strength exercise, BP and lipid control, diabetes screening, and smoking cessation—is central to reducing competing cardiovascular mortality. Routine PET/CT (Option A) is not recommended for asymptomatic survivors of early-stage breast cancer. Tumor markers (Option C) lack specificity/sensitivity and do not improve survival when used for routine surveillance. The APRN should also ensure age-appropriate screenings (mammography for remaining breast tissue), manage endocrine therapy adverse effects if applicable, update vaccinations, and address psychosocial needs, sexual health, and bone health (DEXA as indicated). A shared survivorship care plan detailing treatment exposures, potential late effects, and follow-up responsibilities supports coordinated care with primary providers.

Male BRCA2 carriers have a substantially elevated risk of early-onset, clinically significant prostate cancer. Many expert groups recommend initiating annual PSA testing (with or without digital rectal exam) at age 40 with shared decision-making that covers benefits/harms, downstream biopsy pathways, and management options should an abnormal result occur. MRI is valuable for risk stratification and targeted biopsy after PSA elevation but is not a replacement for primary screening in asymptomatic men (Option C). Delaying until 55 or requiring symptoms (Options A/D) risks missing aggressive disease at a curable stage. The APRN should document family history, discuss lifestyle factors, explain PSA variability (infection, ejaculation), and establish a clear follow-up algorithm for abnormal results (repeat PSA, secondary tests like percent free PSA, MRI, urology referral). Provide education about cascade testing in relatives and coordinate broader BRCA-related risk management (male breast self-awareness, pancreatic screening in select families).